This review discusses the underlying cellular pathology and proposed mechanism of omaveloxolone in FRDA. The MOXIe study is presented in detail, including a discussion of the challenges faced in clinical trials in FRDA, and rare diseases more broadly. Finally, other therapies under investigation are reviewed briefly.
Thursday, August 10, 2023
Omaveloxolone for the Treatment of Friedreich’s Ataxia
Riley Kessler, Sonal Sharma, David R Lynch, Omaveloxolone for the Treatment of Friedreich’s Ataxia, Published Online: Aug 9th 2023
touchREVIEWS in Neurology. 2023;19(2):Online ahead of journal publication.
Subscribe to:
Posts (Atom)
